Copyright © 2005, European Society of Cardiology
Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure
aDepartment of Physiology, BSB 622, New York Medical College, Valhalla, NY 10595, United States
bDepartment of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, United States
cUniversity of Texas Health Science Center at Houston, Brown Foundation Institute of Molecular Medicine, Houston, TX, United States
dCleveland Clinic Foundation, Cleveland, OH, United States
* Corresponding author. Tel.: +1 914 594 4095; fax: +914 594 4018. Email address: fabio_recchia{at}nymc.edu
Objective: Experimental evidence suggests that modulation of myocardial substrate metabolism can markedly affect the progression of chronic heart failure (HF). We tested whether the inhibition of carnitine palmitoyl transferase-I (CPT-I), the enzyme regulating mitochondrial fatty acid oxidation, slows left ventricular remodeling and deterioration of function in pacing-induced HF.
Methods: Normal dogs (n=9) were compared to untreated dogs with pacing-induced HF (n=9) and HF dogs treated with 65 mg/kg/day of oxfenicine (HF+Oxf, n=9), a CPT-I inhibitor.
Results: HF+Oxf reached terminal failure (LV end-diastolic pressure=25 mm Hg) 6 days later than untreated HF (P<0.05). At 28 days of pacing, hemodynamic alterations and LV dilation were significantly attenuated and the 25% decrease in LV wall thickness was completely prevented in HF+Oxf vs. untreated HF, as was the activation of matrix metalloproteinase-2 and -9, markers of tissue remodeling. Oxfenicine also prevented HF-induced transcriptional down-regulation of CPT-I, medium chain acyl-CoA dehydrogenase, GAPDH and citrate synthase, key enzymes of cardiac energy metabolism. In addition, mRNA, but not protein levels of the nuclear receptor peroxisome proliferator-activated receptor-
were reduced in untreated HF, while they did not change significantly in HF+Oxf, as compared to control.
Conclusions: CPT-I inhibition early in the development of HF prevented LV wall thinning and delayed the time to end-stage failure. While these results are limited to an experimental model of disease, they nevertheless suggest that CPT-I inhibition might be effective for slowing the progression of clinical HF.
KEYWORDS Cardiomyopathy; Lipid metabolism; Hemodynamics
Time for primary review 21 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Pellieux, C. Montessuit, I. Papageorgiou, and R. Lerch Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-{alpha} Cardiovasc Res, May 1, 2009; 82(2): 341 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling Cardiovasc Res, February 15, 2009; 81(3): 465 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Qanud, M. Mamdani, M. Pepe, R. J. Khairallah, J. Gravel, B. Lei, S. A. Gupte, V. G. Sharov, H. N. Sabbah, W. C. Stanley, et al. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2098 - H2105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Ussher and G. D. Lopaschuk The malonyl CoA axis as a potential target for treating ischaemic heart disease Cardiovasc Res, July 15, 2008; 79(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Neubauer The Failing Heart -- An Engine Out of Fuel N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ojaimi, K. Qanud, T. H. Hintze, and F. A. Recchia Altered expression of a limited number of genes contributes to cardiac decompensation during chronic ventricular tachypacing in dogs Physiol Genomics, March 14, 2007; 29(1): 76 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Okere, M. E. Young, T. A. McElfresh, D. J. Chess, V. G. Sharov, H. N. Sabbah, B. D. Hoit, P. Ernsberger, M. P. Chandler, and W. C. Stanley Low Carbohydrate/High-Fat Diet Attenuates Cardiac Hypertrophy, Remodeling, and Altered Gene Expression in Hypertension Hypertension, December 1, 2006; 48(6): 1116 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R.B. Dyck, T. A. Hopkins, S. Bonnet, E. D. Michelakis, M. E. Young, M. Watanabe, Y. Kawase, K.-i. Jishage, and G. D. Lopaschuk Absence of Malonyl Coenzyme A Decarboxylase in Mice Increases Cardiac Glucose Oxidation and Protects the Heart From Ischemic Injury Circulation, October 17, 2006; 114(16): 1721 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Stanley, E. E. Morgan, H. Huang, T. A. McElfresh, J. P. Sterk, I. C. Okere, M. P. Chandler, J. Cheng, J. R. B. Dyck, and G. D. Lopaschuk Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2304 - H2309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Stanley, F. A. Recchia, and I. C. Okere Metabolic therapies for heart disease: Fish for prevention and treatment of cardiac failure? Cardiovasc Res, November 1, 2005; 68(2): 175 - 177. [Full Text] [PDF]
|
|
|
|
|
|
H. Rupp, T. P. Rupp, and B. Maisch Fatty acid oxidation inhibition with PPAR{alpha} activation (FOXIB/PPAR{alpha}) for normalizing gene expression in heart failure? Cardiovasc Res, June 1, 2005; 66(3): 423 - 426. [Full Text] [PDF]
|
|